NCT05376150: A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
- State
- Completed
- Phase
- Phase 2
- People
- 168 taking part
- Started
- 19 May 2022
- Primary completion
- 18 Sep 2023
- Arms
- XEN1101 10 mg, XEN1101 20 mg
- Results
- Posted on the registry
- Papers
- doi:10.1001/jamanetworkopen.2025.14278
- 17 May 2022: Trial registered
- 19 May 2022: Trial started
- 16 Oct 2023: Trial completed
- 21 Sep 2026: Trial results posted